CDMO List Labs Joins Forces with Genome & Company

List Labs, a microbiome CDMO (contract development and manufacturing organization), has partnered with Genome & Firm, a clinical-stage biotechnology firm based in the United States. Genome & Company, located in the Republic of South Korea, has engaged in negotiations to purchase a majority stake in List Biological Laboratories, Inc., based in the United States (List Labs).

As a result of the collaboration, the first worldwide live biotherapeutic drug research business with integrated contract development and manufacturing capabilities has been formed.Thanks to the collaboration, List Labs will be able to meet its strategic aim of expanding and expanding capacity, as well as accelerating the deployment of an end-to-end solution for all phases of clinical trial material and commercial manufacturing.

List Labs will keep independent operational supervision of overall client operations, preserving the confidentiality of the contract client’s private information.List Labs will be able to make money by continuing to supply CDMO services to the open market as a result of this. Furthermore, List Labs will continue to provide high-quality bacterial products, such as toxins and cGMP LPS, to its global client base, as it has done since 1978.

The synergistic partnership with Genome & Company will help us achieve our common goal of being the premier worldwide CDMO specializing in the microbiome.Genome & Company CEO Jisoo Pae stated, “Our goal is to forge new ground in the microbiome sector. The development of this distinct and differentiated business model gives two successful, cutting-edge companies with the resources they need to forge new territory.”